×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TAK – takeda pharmaceutical company limited american depositary shares (each representing 1/2 of a share of) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TAK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
08:08 am
tak
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative [Globe and Mail, The (Toronto, Canada)]
Low
Report
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative [Globe and Mail, The (Toronto, Canada)]
12/12
05:30 pm
tak
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
Low
Report
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
12/11
07:14 pm
tak
Dietary Supplements Market in Japan is Expected to Reach USD 2,310.30 Million by 2033, Growing at a 6.2% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Dietary Supplements Market in Japan is Expected to Reach USD 2,310.30 Million by 2033, Growing at a 6.2% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
12/10
04:12 am
tak
Takeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for Growth [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for Growth [Yahoo! Finance]
12/3
07:00 am
tak
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
Low
Report
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
11/30
04:38 pm
tak
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? [Yahoo! Finance]
Low
Report
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? [Yahoo! Finance]
11/29
08:39 am
tak
Takeda Canada co-sponsors grant to boost IBD clinical research [Yahoo! Finance]
Low
Report
Takeda Canada co-sponsors grant to boost IBD clinical research [Yahoo! Finance]
11/28
09:12 am
tak
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease [Globe and Mail, The (Toronto, Canada)]
Low
Report
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease [Globe and Mail, The (Toronto, Canada)]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
06:01 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 18
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 18
12/13
06:13 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 13
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 13
12/2
06:02 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 02
Neutral
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 02
10/31
06:29 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
10/31
06:21 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
10/31
06:20 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
9/26
06:07 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Sep 26
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Sep 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
5.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
TOP News Decliners
3/17
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
-10.1%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: